title: Reply to Rituxan is not associated with Stevens-Johnson syndrome.
authors.affiliation: Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Parise
authors.affiliation: Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Kahle
authors.affiliation: Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Schlaak
authors.affiliation: Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Mauch
authors.affiliation: Department of Dermatology, Skin Cancer Centre, University Hospital of Cologne, Cologne, Germany. Electronic address: peter.kurschat@uk-koeln.de.
authors.forename: P
authors.initials: P
authors.lastname: Kurschat
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal